DRUG
Bright Minds Biosciences Inc.
There isn't enough reported data to score DRUG yet.
DRUG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
DRUG's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
DRUG PE Valuation
DRUG has no meaningful PE right now: it lost money over the past year.
DRUG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect DRUG's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
DRUG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.94 | -$0.86 |
| Q1 2026 | -$2.28 | -$1.76 |
| Q4 2025 | -$1.93 | -$1.76 |
| Q3 2025 | -$1.24 | -$0.75 |
| Q2 2025 | -$1.08 | -$0.42 |
| Q1 2025 | -$0.52 | +$0.44 |
| Q4 2024 | -$0.17 | +$1.10 |
| Q3 2024 | -$0.49 | +$0.94 |
DRUG is still losing money, but far less than before: $1.94 per share over the past year, against $4.72 at its worst in early 2022.
DRUG Quarterly Revenue
DRUG's revenue is shrinking: $0 last quarter.
DRUG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.9M | -$3.5M |
| Q1 2026 | -$6.7M | -$5M |
| Q4 2025 | -$4.1M | -$3M |
| Q3 2025 | -$891.5K | -$565.8K |
| Q2 2025 | -$2.5M | -1559% |
| Q1 2025 | -$1.7M | -$1.1M |
| Q4 2024 | -$1.1M | -$472.7K |
| Q3 2024 | -$325.6K | +$516.3K |
DRUG has burned cash in almost every quarter: −$18M over the past year, against −$6M the year before.
DRUG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +241K shares |
| 1 year | +39% | +2.7M shares |
| 3 years | +161% | +6.1M shares |
| 5 years | +334% | +7.6M shares |
| Available history | +749% | +8.7M shares |
DRUG has 10M diluted shares, up 39% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
DRUG hasn't bought back shares in the past year.
DRUG Net Leverage
DRUG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DRUG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 11.7 | Oversold |
DRUG's weekly RSI is 24 (oversold) and its Stochastic is 12 (oversold).
DRUG PE vs Healthcare Sector
DRUG has no meaningful PE right now: it lost money over the past year.
DRUG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $45.1 | 50% below |
| 20 week MA | $61.1 | 63% below |
| 50 week MA | $72.0 | 68% below |
| 100 week MA | $56.0 | 59% below |
| 200 week MA | $30.8 | 26% below |
DRUG is in a downtrend: it's below all five of its weekly moving averages, and 26% below its 200-week average.
DRUG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $26.8 | $17.0 | -36% |
| 2022 | $17.0 | $4.11 | -76% |
| 2023 | $4.11 | $1.43 | -65% |
| 2024 | $1.43 | $39.9 | +2689% |
| 2025 | $39.9 | $82.1 | +106% |
| 2026 YTD | $82.1 | $22.7 | -72% |
DRUG's yearly returns have swung widely, from +2689% in 2024 to −76% in 2022. It's down 72% so far in 2026.